Cardiometabolic effects of dual GLP-1 and glucagon receptor agonists: a systematic review and meta-analysis of randomised controlled trials

Le résumé fourni par la source

Background: Selective GLP-1-receptor agonists reduce body weight and improve cardiometabolic risk factors. However, whether dual GLP-1 and glucagon receptor agonism modifies these cardiometabolic effects remains unclear. Here, we assessed the effects of dual GLP-1/GCGR agonists on cardiometabolic risk factors across randomised controlled trials. Methods: In this random-effects meta-analysis, MEDLINE, Embase, and CENTRAL were searched from database inception to June 21, 2026, for randomised controlled trials evaluating clinical efficacy of dual GLP-1/GCGR agonists in adults with cardiometabolic disease with a treatment duration ≥12 weeks. The primary outcome was placebo-corrected change in body weight from baseline to end of treatment. Secondary outcomes were changes in waist circumference, atherogenic lipids (total cholesterol, LDL cholesterol, and triglycerides), glycated haemoglobin, and hemodynamic outcomes. Prespecified subgroup analyses evaluated effect modification by dose, treatment indication and the use of an active comparator (selective GLP-1 receptor agonists). Results: 6593 records were identified and 16 trials comprising 6611 participants (47.3% male) were included. Dual GLP-1/GCGR agonists significantly reduced body weight compared with placebo (-7.44% (95% CI [-9.44, -5.43]); -7.27 kg (95% CI [-9.28, -5.27]). Weight loss was accompanied by improvements across all cardiometabolic risk factors. Compared with selective GLP-1 receptor agonists, dual GLP-1/GCGR agonists were associated with a greater reduction in triglycerides (-0.28 mmol/l, 95% CI [-0.50, -0.06]). Discussion: Dual GLP-1/GCGR agonists consistently improved cardiometabolic risk factors across randomised clinical trials and may provide metabolic benefits beyond selective GLP-1 receptor agonists. These findings support further evaluation in large-scale outcome studies. Registration: This study was registered with PROSPERO (CRD420261295754).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.